Oppenheimer is reiterating its Underperform rating on shares of Cadence Pharmaceuticals, Inc. CADX on expectations for a softer than expected OFIRMEV launch.
“We anticipate consensus revenues for OFIRMEV will come down over 2011, pressuring shares,” Oppenheimer writes. “While CPIX's Caldolor (IV ibuprofen) is not a perfect comparator to OFIRMEV, we believe Caldolor's slow market adoption could provide insight into OFIRMEV's early launch trajectory.
“We believe management's expectation for formulary access at 800-1,000 hospitals 12 months following approval could prove aggressive. We believe CADX shares could fall to $4-5 by YE11, with potential for an additional equity offering further pressuring shares.”
Cadence Pharmaceuticals closed Tuesday at $7.66.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in